Gene Therapy of Pancreatic CancerDabernat S1-3*, Lafitte M1,2, Bedel A1-3, Hubert de Verneuil1-3 and Moreau-Gaudry F1-3
- *Corresponding Author:
- Sandrine Dabernat
Université Bordeaux Segalen
INSERM U1035146, rue Léo Saignat
33076 Bordeaux Cedex
E-mail: [email protected]
Received date: April 01, 2013; Accepted date:April 28, 2013; Published date: May 02, 2013
Citation: Dabernat S, Lafitte M, Bedel A, de Verneuil H, Moreau-Gaudry F (2013) Gene Therapy of Pancreatic Cancer. J Genet Syndr Gene Ther 4: 138. doi:10.4172/2157-7412.1000138
Copyright: © 2013 Dabernat S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors with a 5-year survival rate of less than 5%. The poor prognosis of the disease is associated with late diagnosis and a high degree of drug resistance has not been overcome during the past decades. Gemcitabine-based regimens are the first line therapy for advanced pancreatic cancer but are not curative. Recent new combination chemotherapies achieved significant benefits but toxicity makes their use controversial. Novel approaches are currently being developed; in particular cancer gene therapies are undergoing preclinical and clinical validation and are the topic of the present review. We will present different ways to design gene therapy against pancreatic cancers that have been validated in preclinical studies. We also reviewed the clinical trials already published or still ongoing.